Product Overview
[Drug Name]
Generic Name: Losartan Potassium Tablets
Trade Name: BeiZuo Losartan Potassium Tablets 100mg*7 Tablets
Pinyin Full Code: BeiZuo LvShaTanJiaPian 100mg*7 Tablets
[Main Ingredient]
The main ingredient of this product is losartan potassium.
[Indications/Main Functions]
This product is indicated for the treatment of essential hypertension.
[Specifications]
100mg*7 tablets (BeiZuo)
[Dosage and Administration]
For most patients, the usual starting and maintenance dose is 50mg once daily. Maximum antihypertensive effect is achieved after 3 to 6 weeks of treatment. In some patients, increasing the dose to 100mg once daily may produce further antihypertensive effects. For patients with insufficient vascular volume (e.g., those receiving high-dose diuretics), a starting dose of 25mg once daily may be considered (see Precautions). For elderly patients or those with renal impairment, including those undergoing hemodialysis, no adjustment of the starting dose is necessary. A lower dose should be considered for patients with a history of hepatic impairment (see Precautions). This product can be used with other antihypertensive medications. This product can be taken with or without food.
[Adverse Reactions]
This product is well tolerated; adverse reactions are mild and transient, and no cases have required discontinuation of treatment due to adverse drug reactions. The overall incidence of adverse reactions with this product is similar to that with placebo. In controlled clinical studies of primary hypertension, the only drug-related adverse reaction with a higher incidence than placebo in 1% or more of patients treated with this product was dizziness. In addition, orthostatic hypotension, which was dose-related, occurred in less than 1% of patients. Although the incidence of rash in controlled clinical trials was lower than with placebo, it has been reported in isolated cases.
[Contraindications]
This product is contraindicated in patients with hypersensitivity to any component. Symptomatic hypotension may occur in patients with hypotension, electrolyte/fluid imbalance, or vascular volume depletion (e.g., those receiving high-dose diuretics). These conditions should be corrected before treatment with this product, or a lower initial dose should be used. (See Dosage and Administration.) Hepatic Impairment: Pharmacokinetic data indicate that plasma concentrations of losartan are significantly increased in patients with cirrhosis. Therefore, a lower dose should be considered for patients with a history of hepatic impairment (see Dosage and Administration). Renal Impairment: Due to inhibition of the renin-angiotensin system, changes in renal function, including renal failure, have been reported in susceptible individuals; these changes resolve after discontinuation of treatment. Other drugs that affect the renin-angiotensin system may increase blood urea and serum creatinine levels in patients with bilateral renal artery stenosis or unilateral renal artery stenosis. Similar reports have been reported with this product. These changes in renal function resolve after discontinuation of treatment.
[Drug Interactions]
Concomitant use with other medications may result in drug interactions. Consult your physician or pharmacist for details.
